{"id":"placebo-of-aripiprazole","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo of aripiprazole contains no active drug substance and produces no direct pharmacological effect. It is used as a control arm in clinical trials to assess the efficacy of the actual aripiprazole treatment by comparison against a non-active intervention, allowing researchers to distinguish true drug effects from placebo response.","oneSentence":"This is a placebo control formulation with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:36.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials of aripiprazole"}]},"trialDetails":[{"nctId":"NCT03238326","phase":"PHASE3","title":"Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-08-23","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT07215884","phase":"PHASE1","title":"Dopamine and Sensorimotor Function in Stuttering","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-30","conditions":"Stuttering, Adult","enrollment":40},{"nctId":"NCT05545891","phase":"PHASE2","title":"Aripiprazole in Body Focused Repetitive Behaviors","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06","conditions":"Trichotillomania (Hair-Pulling Disorder), Dermatillomania","enrollment":100},{"nctId":"NCT06591091","phase":"PHASE2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-09","conditions":"Depression","enrollment":80},{"nctId":"NCT01490086","phase":"PHASE2","title":"RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Reviva Pharmaceuticals","startDate":"2011-12","conditions":"Acute Schizophrenia, Schizoaffective Disorder","enrollment":234},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":"Psychosis, Negative Symptoms With Primary Psychotic Disorder","enrollment":46},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06589817","phase":"PHASE3","title":"A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","startDate":"2024-10","conditions":"Acute Schizophrenia","enrollment":376},{"nctId":"NCT02918370","phase":"PHASE3","title":"Aripiprazole for Bipolar Disorder and Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-11","conditions":"Bipolar Disorder, Alcoholism, Alcohol Abuse","enrollment":75},{"nctId":"NCT03423680","phase":"PHASE3","title":"A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression","status":"RECRUITING","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2018-02-22","conditions":"Depression, Bipolar","enrollment":390},{"nctId":"NCT06372210","phase":"NA","title":"A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-06-26","conditions":"Mental Disorder, Schizophrenia, Major Depressive Disorder","enrollment":54},{"nctId":"NCT03198078","phase":"PHASE3","title":"Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2017-06-30","conditions":"Schizophrenia","enrollment":316},{"nctId":"NCT00261443","phase":"PHASE4","title":"A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-09","conditions":"Bipolar Disorder","enrollment":1270},{"nctId":"NCT05103410","phase":"PHASE4","title":"Impact of Aripiprazole on Postoperative Analgesia in Laparoscopic Hysterectomy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-11-10","conditions":"Anesthesia, Analgesia, Hysterotomy","enrollment":80},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT00484471","phase":"PHASE4","title":"ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness","status":"COMPLETED","sponsor":"Korea Otsuka International Asia Arab","startDate":"2007-10","conditions":"Bipolar Disorder","enrollment":127},{"nctId":"NCT00468130","phase":"NA","title":"Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-05","conditions":"Autism","enrollment":13},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT02091882","phase":"PHASE4","title":"Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-03-21","conditions":"Device Latency","enrollment":30},{"nctId":"NCT01418339","phase":"PHASE3","title":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07-27","conditions":"Tourette's Disorder","enrollment":135},{"nctId":"NCT01418352","phase":"PHASE3","title":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-08-02","conditions":"Tourette's Disorder","enrollment":83},{"nctId":"NCT00149734","phase":"PHASE3","title":"Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2005-01","conditions":"Schizophrenia","enrollment":8},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT02088697","phase":"PHASE1","title":"A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2013-12","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT03661983","phase":"PHASE4","title":"Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-13","conditions":"Tourette's Disorder (TD)","enrollment":36},{"nctId":"NCT03487783","phase":"PHASE3","title":"Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2018-05-02","conditions":"Tourette Syndrome","enrollment":121},{"nctId":"NCT03487770","phase":"PHASE3","title":"Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2018-04-09","conditions":"Autistic Disorder","enrollment":111},{"nctId":"NCT03172871","phase":"PHASE3","title":"Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2017-05-15","conditions":"Schizophrenia","enrollment":436},{"nctId":"NCT00279409","phase":"PHASE2","title":"Treatment of Children With ADHD Who do Not Fully Respond to Stimulants","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2006-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":10},{"nctId":"NCT02574741","phase":"PHASE2","title":"Combination Treatment for Augmenting Language in Children With ASD","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2012-06","conditions":"Autism Spectrum Disorder","enrollment":58},{"nctId":"NCT01913327","phase":"PHASE4","title":"Antipsychotic Effects on Brain Function in Schizophrenia","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2013-04","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":4},{"nctId":"NCT04234776","phase":"PHASE4","title":"Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2018-04-03","conditions":"Depressive Disorder","enrollment":88},{"nctId":"NCT00780702","phase":"PHASE1","title":"Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2008-05-08","conditions":"Cocaine Dependence, Cocaine-Related Disorders, Opioid-Related Disorders","enrollment":41},{"nctId":"NCT02630888","phase":"PHASE2","title":"Efficacy of Memantine add-on in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2014-08","conditions":"Bipolar Disorder","enrollment":44},{"nctId":"NCT01338298","phase":"NA","title":"Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-01","conditions":"Hyperprolactinemia","enrollment":60},{"nctId":"NCT00198107","phase":"PHASE3","title":"Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism","status":"COMPLETED","sponsor":"Indiana University","startDate":"2005-09","conditions":"Autistic Disorder","enrollment":81},{"nctId":"NCT01469039","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2011-12","conditions":"Schizophrenia","enrollment":623},{"nctId":"NCT00870727","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders","status":"COMPLETED","sponsor":"Indiana University","startDate":"2009-02","conditions":"Pervasive Developmental Disorder","enrollment":33},{"nctId":"NCT01104766","phase":"PHASE3","title":"Safety and Efficacy of Cariprazine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2010-04-23","conditions":"Schizophrenia","enrollment":617},{"nctId":"NCT01567527","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-08","conditions":"Bipolar I Disorder","enrollment":731},{"nctId":"NCT02404532","phase":"PHASE4","title":"Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-02","conditions":"Device Latency","enrollment":30},{"nctId":"NCT02046564","phase":"PHASE3","title":"Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-02","conditions":"Major Depressive Disorder","enrollment":412},{"nctId":"NCT00953745","phase":"NA","title":"Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":43},{"nctId":"NCT00509067","phase":"PHASE2","title":"Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2007-11","conditions":"Schizophrenia","enrollment":43},{"nctId":"NCT01155544","phase":"PHASE4","title":"Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2011-06","conditions":"Substance Abuse, Substance Dependence","enrollment":""},{"nctId":"NCT02168920","phase":"PHASE3","title":"Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-06-11","conditions":"Agitation Associated With Dementia of the Alzheimer's Type","enrollment":150},{"nctId":"NCT00667875","phase":"PHASE2","title":"An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2008-04","conditions":"Alcohol Dependence","enrollment":65},{"nctId":"NCT00373880","phase":"PHASE2","title":"Effects of Aripiprazole on Cocaine Craving and Self-Administration","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2005-04","conditions":"Cocaine Abuse","enrollment":26},{"nctId":"NCT01292057","phase":"PHASE3","title":"Aripiprazole Effects on Alcohol Drinking and Craving","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2011-02","conditions":"Alcohol Dependence","enrollment":99},{"nctId":"NCT00683852","phase":"PHASE3","title":"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-09","conditions":"Major Depressive Disorder","enrollment":225},{"nctId":"NCT00194012","phase":"PHASE3","title":"Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2004-08","conditions":"Bipolar Disorder","enrollment":62},{"nctId":"NCT01617447","phase":"PHASE3","title":"A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-07","conditions":"Autistic Disorder","enrollment":92},{"nctId":"NCT00439634","phase":"PHASE2","title":"Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-02","conditions":"Schizophrenia","enrollment":873},{"nctId":"NCT00905307","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-07","conditions":"Schizophrenia","enrollment":459},{"nctId":"NCT00728312","phase":"PHASE4","title":"Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial","status":"WITHDRAWN","sponsor":"US Department of Veterans Affairs","startDate":"2009-08","conditions":"Methamphetamine Dependence","enrollment":""},{"nctId":"NCT01149655","phase":"PHASE3","title":"Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07","conditions":"Schizophrenia","enrollment":252},{"nctId":"NCT00489866","phase":"PHASE2","title":"Aripiprazole Augmentation of Antidepressants in PTSD","status":"COMPLETED","sponsor":"Durham VA Medical Center","startDate":"2007-03","conditions":"PTSD","enrollment":14},{"nctId":"NCT01663532","phase":"PHASE3","title":"Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-10","conditions":"Schizophrenia","enrollment":340},{"nctId":"NCT01727700","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-11","conditions":"Tourette's Disorder, Tic Disorder","enrollment":133},{"nctId":"NCT01822730","phase":"PHASE4","title":"A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"COMPLETED","sponsor":"Wei Hao","startDate":"2013-02","conditions":"Methamphetamine Dependence","enrollment":120},{"nctId":"NCT01813643","phase":"PHASE4","title":"A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis","status":"TERMINATED","sponsor":"Wei Hao","startDate":"2012-07","conditions":"Methamphetamine Dependence","enrollment":50},{"nctId":"NCT01813656","phase":"PHASE4","title":"An Study of Aripiprazole in the Treatment of Methamphetamine Dependence","status":"TERMINATED","sponsor":"Wei Hao","startDate":"2012-09","conditions":"Methamphetamine Dependence","enrollment":10},{"nctId":"NCT00194077","phase":"PHASE3","title":"Study of Aripiprazole (Abilify) in Children With Symptoms of Mania","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2004-08","conditions":"Bipolar Disorder","enrollment":60},{"nctId":"NCT01161277","phase":"PHASE4","title":"Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2010-08","conditions":"Psychosis, Schizophrenia","enrollment":54},{"nctId":"NCT01520350","phase":"PHASE3","title":"Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study","status":"TERMINATED","sponsor":"Serge Beaulieu","startDate":"2012-02","conditions":"Bipolar Disorder, Depressive Episode","enrollment":2},{"nctId":"NCT00345033","phase":"PHASE4","title":"Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2005-03","conditions":"Schizophrenia, Insulin Resistance","enrollment":38},{"nctId":"NCT01323205","phase":"PHASE2","title":"Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-05","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT01227668","phase":"PHASE4","title":"Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Irritability Associated With Autistic Disorder","enrollment":215},{"nctId":"NCT00606177","phase":"PHASE3","title":"A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-01","conditions":"Bipolar I Disorder","enrollment":99},{"nctId":"NCT00606281","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-01","conditions":"Bipolar I Disorder","enrollment":258},{"nctId":"NCT00876343","phase":"PHASE3","title":"Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":586},{"nctId":"NCT01495156","phase":"PHASE4","title":"Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2011-09","conditions":"Bipolar I Disorder","enrollment":""},{"nctId":"NCT02013232","phase":"NA","title":"Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia","status":"UNKNOWN","sponsor":"Beijing HuiLongGuan Hospital","startDate":"2013-02","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT01438060","phase":"PHASE3","title":"Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2000-08","conditions":"Dementia, Alzheimer Type","enrollment":232},{"nctId":"NCT00665366","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-06","conditions":"Bipolar Disorder Mania","enrollment":493},{"nctId":"NCT00277212","phase":"PHASE4","title":"A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Bipolar Disorder","enrollment":1169},{"nctId":"NCT00337571","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-06","conditions":"Behavioral Symptoms, Autistic Disorder","enrollment":218},{"nctId":"NCT00105196","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-03","conditions":"Major Depressive Disorder","enrollment":349},{"nctId":"NCT00365859","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-09","conditions":"Autistic Disorder, Behavioral Symptoms","enrollment":330},{"nctId":"NCT00332241","phase":"PHASE3","title":"Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-06","conditions":"Autistic Disorder","enrollment":98},{"nctId":"NCT00095758","phase":"PHASE3","title":"A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-09","conditions":"Major Depressive Disorder","enrollment":1200},{"nctId":"NCT00095823","phase":"PHASE3","title":"A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-06","conditions":"Major Depressive Disorder","enrollment":1200},{"nctId":"NCT00080327","phase":"PHASE4","title":"Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-11","conditions":"Schizophrenia","enrollment":370},{"nctId":"NCT00080314","phase":"PHASE3","title":"Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-01","conditions":"Bipolar Disorder","enrollment":400},{"nctId":"NCT00094432","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-06","conditions":"Bipolar I Disorder","enrollment":650},{"nctId":"NCT00095719","phase":"PHASE3","title":"Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-12","conditions":"Dementia, Alzheimer's Disease","enrollment":125},{"nctId":"NCT00095511","phase":"PHASE3","title":"Aripiprazole in Patients With Acute Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-06","conditions":"Bipolar Disorder","enrollment":615},{"nctId":"NCT00082199","phase":"PHASE4","title":"Study of Aripiprazole in Subjects With Alcoholism","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-04","conditions":"Alcoholism","enrollment":400},{"nctId":"NCT00097266","phase":"PHASE3","title":"Study of Aripiprazole in Patients With Acute Bipolar Mania","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-12","conditions":"Bipolar Disorder","enrollment":615},{"nctId":"NCT00325689","phase":"PHASE4","title":"Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":323},{"nctId":"NCT00300846","phase":"PHASE4","title":"A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT00338273","phase":"PHASE3","title":"A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode","status":"WITHDRAWN","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-12","conditions":"Bipolar Disorder","enrollment":""},{"nctId":"NCT00706654","phase":"PHASE3","title":"Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":937},{"nctId":"NCT00706589","phase":"PHASE3","title":"Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2008-10","conditions":"Chronic Motor or Vocal Tic Disorder, Tourette's Disorder","enrollment":61},{"nctId":"NCT00705783","phase":"PHASE3","title":"Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":843},{"nctId":"NCT01082848","phase":"PHASE3","title":"ARIpiprazole in Anorexia NErvosa","status":"UNKNOWN","sponsor":"Juan A. Arnaiz","startDate":"2010-03","conditions":"Anorexia Nervosa","enrollment":60},{"nctId":"NCT00351936","phase":"PHASE4","title":"A Placebo-Controlled, Cross-Over Trial of Aripiprazole","status":"COMPLETED","sponsor":"North Suffolk Mental Health Association","startDate":"2005-12","conditions":"Schizophrenia","enrollment":16},{"nctId":"NCT00102063","phase":"PHASE3","title":"Aripiprazole in Adolescents With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":302},{"nctId":"NCT01556763","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia","status":"COMPLETED","sponsor":"FORUM Pharmaceuticals Inc","startDate":"2008-04","conditions":"Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of Aripiprazole","genericName":"Placebo of Aripiprazole","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trials of aripiprazole.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}